ASX - Delayed Quote AUD

Bio-Gene Technology Limited (BGT.AX)

Compare
0.0490
-0.0030
(-5.77%)
At close: 4:10:45 PM GMT+11

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Mr. Timothy Owen Grogan B.Sc., LLB MD, CEO & Director 285.63k -- --
Mr. Edmond Tern B.A., CPA CFO & Company Secretary 125.43k -- --
Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A., MBA Executive Director of Research & Development and Executive Director 238.43k -- --

Bio-Gene Technology Limited

400 Collins Street
Level 6
Melbourne, VIC 3000
Australia
61 3 9068 1062 https://www.bio-gene.com.au
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University to support research and field operations relating to processing and distillation of oil from biomass; AgriFor Scientific, a chemistry product; cesar for assessing the insecticidal activity of molecules against a various insect species; CSIRO, a chemistry development process; Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University, a chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.

Corporate Governance

Bio-Gene Technology Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 24, 2025 at 10:59 AM UTC - February 28, 2025 at 12:00 PM UTC

Bio-Gene Technology Limited Earnings Date

Recent Events

Related Tickers